Key facts
- Notable investors include Tailong VC, Hangzhou Capital, BOHE Angel Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Pulse Peak Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Pulse Peak Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pulse Peak Pharmaceuticals
Operator of a clinical research organization intended to support the full lifecycle of drug development studies. The company offers biology-analysis laboratories, international-trial auditing capabilities, and data-statistics integration, enabling pharmaceutical sponsors and biotech enterprises to generate quality clinical evidence.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2014
- Employees
- 5
- Website
- maypharm.cn/
- Ownership
- Privately Held (backing)
Pulse Peak Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pulse Peak Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pulse Peak Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.